Home › Cancer (all types) › Washington › Spokane Valley
Cancer (all types) clinical trials in Spokane Valley, WA
4 studies for Cancer (all types) are looking for participants at sites in and around Spokane Valley (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- Cancer Care Northwest, Spokane Valley
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecruitingPhase 3
- Kootenai Clinic Cancer Services - Post Falls, Post Falls · 14 mi away
- Kootenai Health - Coeur d'Alene, Coeur d'Alene · 21 mi away
Molecular Genetics Studies of Cancer Patients and Their Relatives
RecruitingObservational studyHealthy volunteers welcome
- Kootenai Cancer Center, Post Falls · 14 mi away
GEMINI-NSCLC: NSCLC Biomarker Study
RecruitingObservational study
- Cancer Care Northwest, Spokane Valley
About Cancer (all types)
If you or someone you love has been diagnosed with cancer, learn about diagnosis, treatment, risk factors, coping and much more.
More about Cancer (all types) on MedlinePlus
Cancer (all types) trials in other cities
- Houston, TX121 studies
- New York City, NY110 studies
- Boston, MA86 studies
- Los Angeles, CA73 studies
- Nashville, TN65 studies
- Philadelphia, PA59 studies
- Durham, NC58 studies
- Washington, DC58 studies
- Chicago, IL51 studies
- Seattle, WA49 studies
- Atlanta, GA49 studies
- Arlington, VA48 studies
Other studies in Spokane Valley
- Non-Small Cell Lung Cancer14 studies
- Prostate Cancer9 studies
- Lung Cancer8 studies
- Breast Cancer8 studies
- Acute Myeloid Leukemia7 studies
- Melanoma6 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Metastatic Cancer4 studies
- Colorectal Cancer4 studies
- Colon Cancer4 studies
- Bladder Cancer4 studies
- Endometrial Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.